

CYANOTECH CORP  
Form 8-K  
September 28, 2007

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## Form 8-K

Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

September 24, 2007

Date of report (Date of earliest event reported)

## Cyanotech Corporation

(Exact name of registrant as specified in its charter)

**NEVADA**  
(State or other jurisdiction of  
incorporation)

**000-14602**  
(Commission File Number  
Number)

**91-1206026**  
(IRS Employer Identification  
Number)

**73-4460 Queen Kaahumanu Highway, Suite #102, Kailua Kona, HI 96740**  
(Address of principal executive offices)

**(808) 326-1353**  
(Registrant's telephone number)

**Not Applicable**  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events**

On September 24, 2007, at Cyanotech Corporation's Annual Meeting of Stockholders, Chairman, President and CEO, Gerald R. Cysewski, Ph.D, said that as a part of its plan to return the Company to profitability, the Company will be emphasizing human nutritional products and that the Company has introduced a new product called M.D. Formulas Hawaii. The M.D. Formulas Hawaii product line combines the Company's BioAstin natural astaxanthin with other healthful ingredients.

During the Company's Annual Meeting of Stockholders, all Directors were re-elected.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CYANOTECH  
CORPORATION (Registrant)

September 28, 2007

By: /s/ William R. Maris  
William R. Maris  
Chief Financial Officer  
and VP of Finance and Administration